Return to The JAM Blog

Incyte knocking on the door of a new upward trend after today’s 6% pop

Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte's (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte's Jakafi in combination with corticosteroids in patients with acute graft-versus-host disease who failed to respond adequately to corticosteroids […]

To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.